New Hope for heart Patients: Combining Imaging Tech with Diabetes Drug Shows Promise
A new study offers a promising approach to reducing heart risks for people with type 2 diabetes and coronary artery disease. Researchers at the University of Hong Kong (HKUMed), working with the University of Hong Kong–Shenzhen Hospital, found that using a special heart imaging technology called the caFFR system alongside SGLT2 inhibitors – a type of diabetes medication – can significantly lower the chances of major heart problems, heart failure, and death.
The caFFR system provides detailed images of coronary arteries, helping doctors assess blood flow. SGLT2 inhibitors, originally developed to manage blood sugar, have recently shown benefits for heart health. This study demonstrates the power of combining these two approaches.
“This research highlights a potential new strategy for managing patients with both type 2 diabetes and coronary artery disease,” says a statement from HKUMed. The study suggests that identifying areas of reduced blood flow with caFFR and then using SGLT2 inhibitors can led to better outcomes.
Major adverse cardiovascular events (MACE) encompass a range of serious heart-related issues, including heart attacks and strokes. By reducing the risk of MACE, heart failure, and death, this combined approach could dramatically improve the quality of life for millions of people living with these conditions.
The findings offer a more personalized approach to heart care, allowing doctors to tailor treatment plans based on individual patient needs and the specific condition of their coronary arteries. Further research is ongoing to confirm these results and explore the full potential of this combined therapy.
